MassBio is partnering with LG Chem and AVEO on February 27, 2024, to host LG Chem AVEO Pharma Day® 2024, an unparalleled opportunity for emerging innovators to learn from and connect with a leading global chemical company and an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer.
What They’re Saying: “LG Chem and AVEO Oncology are dedicated to our shared mission of providing innovative solutions to improve cancer patient’s lives. The collaborative synergy between LG Chem and AVEO Oncology establishes a global oncology organization with a robust portfolio of innovative products and deep capabilities from discovery to clinical, biologics manufacturing and U.S. commercialization. In Boston, where breakthroughs happen and collaborations thrive, LG Chem / AVEO Oncology pharma day will be your gateway to unparalleled opportunities to partner with a nimble and driven biotech culture of AVEO Oncology backed by the spirit of innovation and global resources of LG Chem. We look forward to unfolding a new chapter of strategic partnerships to improve lives of the cancer patients we serve.”
Stella S. Huh (Vice President, Head of Business Development, LG Chem Life Sciences) and Michael P. Bailey (President and CEO, AVEO Oncology)
Hear the latest: During LG Chem/AVEO’s open information session, you’ll discover the latest insights on their R&D strategy, target therapeutic areas, and partnering capabilities. This session will be followed by a networking reception.
- Register to attend the information session and reception today.
Get closer: Innovators with a pre-clinical / clinical candidate who are actively looking for partnership opportunities are encouraged to apply for a one-on-one meeting with LG Chem / AVEO representatives. LG Chem / AVEO’s target therapeutic areas are:
- Oncology (solid tumors / hematological malignancies)
- Metabolic diseases (diabetes, NASH, etc)
- Immunology
If your company meets their eligibility guidelines, apply for a 1:1 by January 5, 2024 at 11:59 PM ET.